Related news from
Wed, 17 Apr 2024 22:15:18 +0000	Why Exact Sciences (EXAS) Dipped More Than Broader Market Today Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.
Wed, 17 Apr 2024 15:07:22 +0000	Exact Sciences Corporation's (NASDAQ:EXAS) Profit Outlook With the business potentially at an important milestone, we thought we'd take a closer look at Exact Sciences...
Mon, 15 Apr 2024 10:52:00 +0000	Exact Sciences names Aaron Bloomer CFO The executive will succeed Jeff Elliott, who said in January he would step down due to personal reasons.
Mon, 15 Apr 2024 10:00:00 +0000	Exact Sciences Names Aaron Bloomer as New Chief Financial Officer MADISON, Wis., April 15, 2024--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the appointment of Aaron Bloomer as chief financial officer (CFO), effective May 15, 2024.
Fri, 12 Apr 2024 11:00:04 +0000	Here’s Why Exact Sciences Corporation (EXAS) Declined in Q1 Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. In the first quarter, the fund’s Investor Class fund ARTMX returned 10.41%, Advisor Class fund APDMX posted a return of 10.40%, and Institutional Class fund APHMX returned 10.44%, compared […]
Thu, 11 Apr 2024 14:00:00 +0000	Myriad Genetics (MYGN) Announces Favorable Research Results Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.
Thu, 11 Apr 2024 11:52:00 +0000	Zacks Investment Ideas feature highlights: Exact Sciences, Kaiser Aluminum and Atmus Filtration Technologies Exact Sciences, Kaiser Aluminum and Atmus Filtration Technologies are part of the Zacks Investment Ideas article.
Thu, 11 Apr 2024 10:00:00 +0000	Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes MADISON, Wis., April 11, 2024--Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on April 10, 2024 it entered into privately negotiated exchange and purchase agreements (the "Agreements") with certain holders of the Company’s 0.3750% Convertible Senior Notes due 2028 (the "Existing Notes"). Pursuant to the Agreements, the Company has agreed to issue to the holders $620.7 million aggregate principal amount of a n
Wed, 10 Apr 2024 22:15:19 +0000	Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know Exact Sciences (EXAS) closed at $73.60 in the latest trading session, marking a -0.89% move from the prior day.
Wed, 10 Apr 2024 19:27:00 +0000	3 Buy-Rated Stocks Flexing Relative Strength While the market has taken a small breather as of late, there have been many big-time winners throughout the last month, including these three. Analysts are bullish on their outlooks, with all three carrying a favorable Zacks Rank.
Wed, 10 Apr 2024 12:16:00 +0000	Search for Cancer Blood Test Continues Despite Illumina-Grail Deal’s Failure Investors shelved their hopes for a pioneering cancer blood test after Illumina ‘s $8 billion acquisition of start-up Grail was scuttled by antitrust regulators last year. A decade from now, these blood tests could be used to flag the more than 60% of deadly cancers that currently lack any way to screen for them. At the annual meeting of the American Association for Cancer Research in San Diego, Exact Sciences reported on a 6,000-sample study of a multi-cancer test it plans to offer alongside single-cancer screening products such as its well-known Cologuard stool-based test for colon cancer.
Wed, 10 Apr 2024 04:00:45 +0000	ZTS, EXAS, AZN: Which Biotech Stock Is the Better Buy? Despite the market’s hot year-to-date run, there’s no shortage of affordable stocks that also have impressive growth profiles. In the biotech scene, numerous firms can harness a technological edge to improve various aspects of health and medicine. From genetic medicine to less-invasive disease diagnostics, this piece will check out three Strong-Buy-rated stocks—ZTS, EXAS, and AZN—that I view as among the most investable in the often-choppy biopharmaceutical scene. Though individual biotech and b
Tue, 09 Apr 2024 11:37:17 +0000	11 Best Biotech ETFs To Buy In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]
Mon, 08 Apr 2024 16:05:00 +0000	Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024 MADISON, Wis., April 08, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity of the company’s multi-biomarker class approach across a broad range of cancer types, including the mos
Mon, 08 Apr 2024 11:00:00 +0000	Sorry, but Blood Tests Won’t Replace Stool Samples or Colonoscopies Yet Disappointing results for colon-cancer blood tests strengthen the investment thesis for Exact Sciences, which makes a stool-based test.
Mon, 08 Apr 2024 10:00:00 +0000	Exact Sciences Schedules First Quarter 2024 Earnings Call MADISON, Wis., April 08, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Fri, 05 Apr 2024 20:16:35 +0000	The 3 Best Cathie Wood Stocks to Buy in April 2024 Full disclosure, I’m not a tremendous fan of Cathie Wood. Generally, I think she makes some terrible picks. For example, what many would consider the best Cathie Wood stocks to buy in April, and her two largest holdings were Coinbase (NASDAQ:COIN) and Tesla (NASDAQ:TSLA). Both companies’ valuations are in the stratosphere. And Coinbase is facing tremendous competition from Bitcoin (BTC-USD) ETFs, along with a potentially ruinous lawsuit by the SEC. Meanwhile Tesla is struggling amid a huge amoun
Fri, 05 Apr 2024 14:16:00 +0000	Freenome’s colorectal cancer blood test data underwhelm analysts Cowen analysts said Freenome’s results are good news for competitors Exact Sciences and Guardant Health.
Thu, 04 Apr 2024 14:15:00 +0000	1 Beaten-Down Cathie Wood Stock to Buy and Hold This company is innovating where it matters most, which could prove highly lucrative down the road.
Thu, 04 Apr 2024 10:05:00 +0000	Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment ROCHESTER, Minn. & MADISON, Wis., April 04, 2024--Exact Sciences and Mayo Clinic advance precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients